It was suspected that aristolochic acid-induced mutations may be associated with hepatitis B virus (HBV), playing an important role in liver carcinogenesis. The purpose of this study was to investigate the association between the use of Chinese herbs containing aristolochic acid and the risk of hepatocellular carcinoma (HCC) among HBV-infected patients. We conducted a retrospective, population-based, cohort study on patients older than 18 years who had a diagnosis of HBV infection between January 1, 1997 and December 31, 2010 and had visited traditional Chinese medicine clinics before one year before the diagnosis of HCC or the censor dates. A total of 802,642 HBV-infected patients were identified by using the National Health Insurance Research Database in Taiwan. The use of Chinese herbal products containing aristolochic acid was identified between 1997 and 2003. Each patient was individually tracked from 1997 to 2013 to identify incident cases of HCC since 1999. There were 33,982 HCCs during the follow-up period of 11,643,790 person-years and the overall incidence rate was 291.8 HCCs per 100,000 person-years. The adjusted hazard ratios (HRs) were 1.13 (95% confidence interval [CI], 1.11-1.16), 1.21 (95% CI, 1.13-1.29), 1.37 (95% CI, 1.24-1.50) and 1.61 (95% CI, 1.40-1.84) for estimated aristolochic acid of 1-250, 251-500, 501-1,000 and more than 1,000 mg, respectively, relative to no aristolochic acid exposure. Our study found a significant doseresponse relationship between the consumption of aristolochic acid and HCC in patients with HBV infection, suggesting that aristolochic acid which may be associated with HBV plays an important role in the pathogenesis of HCC.
There were a series of studies of Chinese herbs containing aristolochic acid that reported increased risks of chronic kidney disease, kidney failure and urinary tract cancers in Taiwan. [5] [6] [7] In addition, increased risk of kidney failure and urinary tract cancers were also found among Chinese herbalists. [8] [9] [10] [11] Further, Chen et al. investigated 152 patients with upper urinary tract urothelial carcinoma and found the 93 had been exposed to aristolochic acid based on the presence of aristolactam-DNA adducts and AA-mutational signature in the renal cortex. 12, 13 Finally, aristolactam-DNA adducts were also detected in 76% of clear cell renal cell carcinoma (ccRCC) and AA-mutational signature was evident in 6 of 10 sequenced ccRCC exomes from Taiwanese patients. 14 Aristolochic acid treatment in rat resulted in DNA adduct formation, and increased mutant frequency in the liver as well as kidneys. 15 It was suspected that aristolochic acidinduced mutations in concert with hepatitis B virus (HBV) play an important role in liver carcinogenesis. 16, 17 Hepatitis B virus (HBV) infection is prevalent in Taiwan, especially before the implementation of the nationwide hepatitis B vaccination program in July 1984. [18] [19] [20] Although plants containing aristolochic acid were prohibited in several countries and in Taiwan in  November 2003 21 approximately one-third of people in Taiwan had been prescribed Chinese herbs containing aristolochic acid between 1997 and 2003. 22 The purpose of this study was to investigate the association between the use of herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma (HCC) among HBV-infected patients.
Methods

Data source
We used the National Health Insurance (NHI) Research Database. The NHI program provides compulsory universal health insurance, implemented on March 1, 1995 , that covers health care services from western medicine to traditional Chinese medicine, from dental care to parturition, and from preventive services to elderly home care in around 99% of the island's population. We used databases for admissions and outpatient visits, both of which included information on patient characteristics, including sex, date of birth, date of admission, date of discharge, dates of visits and up to five discharge diagnoses or three outpatient visit diagnoses by International Classification of Diseases, Ninth Revision (ICD-9) classification. The data files also contained information on patient prescriptions, including the names of prescribed drugs, dosage, duration and total expenditure. We conducted a population-based cohort study on patients older than 18 years who had a diagnosis of HBV infection (ICD-9 2.04, 0.63, 0.009, 0.026 and 0.042 mg, respectively. [26] [27] [28] [29] [30] The weight of patients was not available through the database; therefore, the AA intakes are presented as the total AA intake in mg, instead of showing it as milligrams per kilogram of body weight.
Diagnosis of hepatocellular carcinoma
Patients with HCC (ICD-9 code 155.0) were identified in the admission files with the first-time diagnosis date as the index date. For the diagnosis of HCC, the American Association for the Study of Liver Diseases Practice Guidelines were recommended by the Bureau of NHI. 31 Only patients admitted for HCC were included to increase the validity of the diagnosis. Newly diagnosed patients between January 1, 1999 and December 31, 2013 were further analyzed to allow at least 2 years for subjects to accumulate doses of herbal medicine sufficient to induce HCC.
Potential confounders
Comorbidities, identified in a systematic way, were treated as potential confounders defined by the following diagnoses recorded between January 1, 1997 and one year before the (272) and chronic obstructive pulmonary disease (491 and 492). The prescriptions of medications that could confound the association between taking herbal medicine containing aristolochic acid and cancer risk were further identified, including anti-HBV treatments (i.e., interferon, lamivudine, entecavir, adefovir dipivoxil and telbivudine), aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors (i.e., captopril, enalapril, lisinopril, perindopril, ramipril, quinapril, benazepril, cilazapril and fosinopril), metformin and statins (i.e., simvastatin, lovastatin, atorvastatin, fluvastatin, pravastatin and rosuvastatin). Sociodemographic characteristics (age, sex, income and level of urbanization) were also considered in the model. Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications, with level I referring to the most urbanized communities and level IV referring to the least urbanized communities.
Statistical analyses
We used the Kaplan-Meier method to estimate HCC cumulative incidences. The log-rank test was performed to examine differences in the risk of HCC in the cohort. We also used the direct method to adjust the incidence rates according to the age and sex distribution of the general population of Taiwan during the period 1999-2013. Finally, Cox proportional hazards models were used to compute the hazard ratios (HRs) and accompanying 95% CIs before and after adjustment for the variables including sex, age, monthly income, urbanization, liver cirrhosis and diabetes. 32, 33 Deceased patients (with a death date in the admission file) and those from the beneficiaries who were lost to follow-up were censored. We conducted sensitivity analyses to evaluate the difference and consistency between taking herbal medicine containing aristolochic acid and the risk of HCC and to test for interaction in the subgroup effects. Cox proportional hazards regression models with two-year induction time, competing mortality, propensity score matching and time-dependent covariates were also used to estimate the relationship between estimated aristolochic acid and HCC to avoid potential confounding or time-related biases. A two-tailed p value of 0.05 was considered significant. All these analyses were conducted using SAS statistical software (version 9.4; SAS Institute, Cary, NC).
Results
A total of 802,642 HBV-infected patients were included in the study cohort, of whom 59.4% had taken herbal medicine containing aristolochic acid, respectively. Cancer Epidemiology demographic characteristics, medical conditions and medication use of patients. There were 33,982 HCCs during the follow-up period of 11,643,790 person-years and the overall incidence rate was 291.8 HCCs per 100,000 person-years. There was a higher risk (adjusted HR, 1.14; 95% CI, 1.12-1.17) of HCC in patients with HBV infection who took herbal medicine containing aristolochic acid (Table 2) . Elevated HRs were also found for using >60 g of Guan Mu Tong and 200 g of Guang Fang Ji (Supporting Information, Table S1 ).
Regarding the cumulative dose of aristolochic acid, there were increasing trends in the age-sex standardized incidences associated with dose from none to >1,000 mg in the HBVinfected cohorts (Fig. 2) . The adjusted HRs were 1.13 (95% CI, 1.11-1.16), 1.21 (95% CI, 1.13-1.29), 1.37 (95% CI, 1.24-1.50), and 1.61 (95% CI, 1.40-1.84) for estimated aristolochic acid of 1-250, 251-500, 501-1,000 and >1,000 mg, respectively, relative to no aristolochic acid exposure. There was also a significant dose-response trend (p < 0.0001) when we applied the exposure variable as a continuous variable for 100-mg increase of estimated aristolochic acid ( Table 2 ). The log-rank tests revealed significant observed differences (p < 0.001) over the entire Kaplan-Meier curves (Fig. 3) .
We still observed significantly higher risks of HCC in patients with HBV when using Cox proportional hazards regression with 2-year induction time, competing mortality, propensity score matching and time-varying changes. Additional covariates in the sensitivity analysis had only a little change in the estimates of the association between estimated aristolochic acid and the risk of HCC by different models. When the data were stratified according to sex, age, liver cirrhosis, alcohol-related disease, nonalcoholic steatohepatitis, diabetes, anti-HBV treatment, aspirin, metformin or statin use, the estimates of the association almost remained significant in the subgroup analysis (Table 3 ).
Discussion
We found higher risks of HCC in patients with HBV infection who took herbal medicine containing aristolochic acid. In addition, there were increasing trends in the adjusted HRs associated with estimated aristolochic acid dose from none to >1,000 mg. This study has a number of strengths. First, the study population was taken from a large size population-based computerized database in Taiwan. Because the patients were recruited from an insured general population, we can rule out the possibility of selection bias and losses to follow up. Second, because the NHI reimbursement database collects all prescription information prospectively, we can rule out the possibility of recall bias for the intake doses of various herbal medicine and aristolochic acid. Third, we included a welldefined clinical endpoint, HCC, to examine the clinical significance of the research question in the longitudinal analyses. Fourth, we allowed a minimum induction time of one year and calculated the cumulative dose up to one year before diagnosis or the censor dates. Finally, we conducted sensitivity analyses by analytical designs, potential confounders and stratification, and the results revealed no significant changes in the HRs of the different models and subgroups.
In the HBV-infected cohorts, 59.4% of patients had taken herbal medicine containing aristolochic acid before their prohibition in November 2003 (Table 1) . Among the top ten Chinese herbal formula prescribed for chronic hepatitis in Taiwan during 2002, 34 two types of herbal medicine-Long Dan Xie Gan Tang and Gan Lou Xiao Du Dan-contained 40.8% and 6% Mu Tong, respectively. More than 84% of Mu Tong herbal formulas contained Guan Mu Tong (Aristolochia manshuriensis), and the estimated average dose of aristolochic acid per 1 g of Guan Mu Tong was 2.59 mg. 20 Therefore, patients with HBV virus infection were more likely to take herbal medicine containing aristolochic acid than general population. 19 In our study, aristolochic acid may increase the risks for HCC in HBV-infected patients in a dose-dependent manner (Table 2 ). Mutational signature of AA exposure in humans, cell culture models and animals, suggests that AA mutagenesis and carcinogenesis are mediated by the formation and persistence of aristolactam(AL)-DNA. 35 Although aristolochic acid treatment resulted in significant increases in DNA adduct formation, mutant frequency, and tumors in rat kidneys, the same treatment did not produce tumors in rat liver, while it did induce DNA adducts and mutations in this tissue at lower levels than in the kidney. 15 However, Poon et al. screened 93 HBV-positive HCC genomes/exomes and identified aristolochic acid-like mutational signatures and about twice as many A > T mutations on the nontranscribed strand as on the transcribed strand in 11 probable AA-exposed patients. 17 Rossiello et al. reported that a single nonnecrogenic dose of AA initiated liver cell carcinogenesis which was then promotable to form hepatic foci and nodules. 36 Ng et al. 37 sequenced the whole exomes of 98 hepatocellular carcinomas (HCCs) from two hospitals in Taiwan and found that 78% showed the distinctive mutational signature of aristolochic acid (AA) exposure. Asia, especially Taiwan, appears to be much more extensively affected by AA exposure in the world. Thus, it became clear that AA carcinogenesis is not limited to the upper urinary tract.
Consumption of >60 g of Guan Mu Tong or >200 g of Guang Fang Ji was suggested to be associated with an increased risk of HCC in patients with HBV infection (Supporting Information, Table S1 ). Similarly, >60 g of Mu Tong was also associated with an increased risk of developing urinary tract cancer 7 and >60 g of Mu Tong or Fang Ji was associated with an increased risk of developing kidney failure. 6 Moreover, Mu Tong and Fang Ji contain much higher aristolochic acid than the other medicinal herbs such as Ma Dou Ling, Qing Mu Xiang, Tian Xian Teng and Xi Xin. [24] [25] [26] [27] [28] We also found higher incidences of chronic kidney disease and upper tract urothelial and bladder cancers in patients with HBV infection who took herbal medicine containing aristolochic acid as well as in patients without HBV infection (Supporting Information, Table S2 ). This evidence is in agreement with current knowledge [1] [2] [3] [4] and confirm our previous studies. [5] [6] [7] [8] [9] [10] [11] Other than hepatorenal syndrome in individuals with cirrhosis or fulminant liver failure, aristolochic acid related nephropathy explains in part that HBV infection was associated with the increased risk of chronic kidney disease among patients in Taiwan 38, 39 and there were high incidences of urinary tract cancers in HCC patients subsequently. 40 In addition, exposure to aristolochic acid can also partially explain that high incidence of HCC in dialysis patients with HBV infection in the opposite direction. 41 However, the increased risk shown in the analysis could be due to confounding by disease severity, as patients with more severe forms of hepatitis and thus a higher risk of liver cancer would be more likely to receive these herbs. First, although laboratory data were not available in the claim database, there were similar in the baseline laboratory data of the patients with HBV infection in the subcohort study between January 2001 and October 2003 (Supporting Information, Table S3 ). Second, the dose-dependent manner of aristolochic acid remained either in noncirrhotic or in cirrhotic subgroups (Table 3) . Third, aristolochic acid consumption was assessed between 1997 and 2003, the year of market withdrawal, cases of HCC were identified from 1999 until 2013, that is, 10 years after market withdrawal. Therefore, the 3 The estimated aristolochic acid was divided into only two categories of use (1-250 and >250 mg) in the model with time-varying changes. 4 The models were adjusted for covariates in the main model and each additional listed covariate.
confounding by disease severity, if existed, would tend to be trivial.
Other potential limitations of this study should be considered. Because the data on drug prescriptions were not complete in 1996, we included herbal medicine containing aristolochic acid after 1997 so that the use of these drugs before 1997 would not be captured in our analysis. This could have underestimated the actual ingested dosage. In addition, we presumed that all prescribed medications were actually taken by patients as prescribed, which may overestimate the actual ingested dosage because some degree of noncompliance is always expected. Furthermore, there were additional sources of uncertainty in estimating aristolochic acid exposure, for example, varying concentration of aristolochic acid in a given herbal medicine, possible exposure through mistakenly identified herbs, and possible exposure though herbs obtained through channels other than licensed clinics. These could result in bias to the null hypothesis. Finally, several unmeasured confounders, including body mass index, smoking, alcohol intake and exposure to aflatoxin B1 which are associated with HCC 17, 42, 43 were not included in our database. We used alcohol-related disease, nonalcoholic steatohepatitis, hypertension, hyperlipidemia and chronic obstructive pulmonary disease as additional covariates in the sensitivity analyses. The estimates did not change significantly, that is, no apparent confounding effects were found (Table 3) .
Our study first found significant dose-response relationships between the consumption of aristolochic acid and HCC in patients with HBV infection, suggesting that aristolochic acid which may be associated with HBV plays an important role in the pathogenesis of HCC. Further mechanistic research is needed. Although herbal medicine containing aristolochic acid has largely been banned in Taiwan and many other countries, patients with HBV infection, who have taken those herbs, should be closely followed up.
